Medicinal cannabis hub
Information about access pathways for medicinal cannabis products.
The medicinal cannabis hub brings together information on the regulation of medicinal cannabis in Australia along with guidance material and information resources for consumers, health professionals and sponsors.
While the TGA regulates the access, most medicinal cannabis products are considered to be unapproved medicines. Unapproved medicines have not been assessed by the TGA for safety, quality or effectiveness.
However, where clinically appropriate, there are pathways for registered health care professionals to access medicinal cannabis products for their patients.
For completeness, the medicinal cannabis hub also contains information relating to cannabis vapes.
- Applications and reporting
- Medicinal cannabis products by active ingredients
- Resources, clinical trials and clinical evidence
- Presentation: TGO93 testing and regulation of medicinal cannabis
Frequently asked questions
- Access to medicinal cannabis products
- Accessing medicinal cannabis for a patient
- Importation, manufacture and supply of unapproved medicinal cannabis products
- Medicinal cannabis Special Access Scheme Category A data
- Medicinal cannabis Special Access Scheme Category B data
- Webinar presentation: Medicinal cannabis - Changes to Special Access Scheme (SAS) and Authorised Prescriber applications, 22 November 2021
- Webinar presentation: Medicinal cannabis - Changes to sponsor requirements for supplying unapproved medicinal cannabis products in Australia, 22 November 2021
- Webinar presentation: Medicinal cannabis - Changes to Special Access Scheme (SAS) and Authorised Prescriber applications, 23 November 2021
- Webinar: Medicinal cannabis reforms
- If your business is involved with medicinal cannabis, read our updated guidance about advertising medicinal cannabis to consumers.
- Court proceedings initiated against CDA Clinics QLD Pty Ltd and its former director for alleged unlawful advertising of medicinal cannabisWe have alleged that the advertising on the company's website and social media was unlawful because medicinal cannabis products are prescription-only medicines that can't be advertised directly to consumers.
- Naturally Elevated Pty Ltd and an individual fined $138,600 for alleged unlawful advertising of medicinal cannabisWe have issued infringement notices to the company Naturally Elevated Pty Ltd and an individual for the alleged unlawful advertising of medicinal cannabis on websites and social media pages.
- This publication outlines our plan to transition to a paperless model for Special Access Scheme (SAS) and Authorised Prescriber (AP) submissions. From 1 July 2024 we will only accept submissions via the SAS/AP Online System.
- Public notice of the delegate's final decision to amend the Poisons Standard in relation to cannabidiol (private application and delegate initiated) - Joint ACMS-ACCS #25 and #26 (June and November 2020).